Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 23, 2025 08:05 ET | Source: Imunon, Inc.

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer

Data show continuous clinically significant improvement, with median 13-month and 3-month increases in overall and progression-free survival, respectively, in treatment group Women treated with...
June 06, 2023 12:42 ET | Source: American Oncology Network

American Oncology Network Announces List of Research Studies Presented at the ASCO 2023 Annual Meeting

FORT MYERS, Fla., June 06, 2023 (GLOBE NEWSWIRE) -- American Oncology Network, LLC (AON) announced that six research papers, co-authored by AON physicians and the vice president of pharmacy...
June 06, 2022 16:30 ET | Source: Checkpoint Therapeutics, Inc

Checkpoint Therapeutics Announces Presentation of Pivotal Trial Results of Cosibelimab at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

WALTHAM, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the...
May 13, 2020 17:02 ET | Source: Vaccinex, Inc.

Vaccinex to Present Updated Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting

ROCHESTER, N.Y., May 13, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
July 31, 2019 07:30 ET | Source: Vaccinex, Inc.

Vaccinex Announces $13.8 Million Private Placement

ROCHESTER, N.Y., July 31, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
June 03, 2019 08:00 ET | Source: Vaccinex, Inc.

Vaccinex Presents Updated Interim Results from a Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Non-Small Cell Lung Cancer at the 2019 ASCO Annual Meeting

ROCHESTER, N.Y., June 03, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
May 15, 2019 08:10 ET | Source: Vaccinex, Inc.

Vaccinex Announces Poster Presentations at the 2019 ASCO Annual Meeting

ROCHESTER, N.Y., May 15, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s...